Last update 21 Nov 2024

Centanafadine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CTN SR, CTN-SR, Centanafadine
+ [10]
Mechanism
Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors
Therapeutic Areas
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC15H15N
InChIKeyHKHCSWPSUSWGLI-CABCVRRESA-N
CAS Registry924012-43-1
View All Structures (2)

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Binge-Eating DisorderPhase 2
US
14 Feb 2023
Depressive Disorder, MajorPhase 2
US
12 Sep 2022
Attention Deficit Disorder With HyperactivityPhase 2
AU
01 Dec 2015
Smoking CessationPreclinical
US
15 Sep 2021
Attention Deficit DisorderPreclinical
US
16 Jan 2019
Drug abusePreclinical
US
01 May 2014
NeuralgiaPreclinical
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
662
(Prior Centanafadine SR 200 mg)
fexrndbawt(tbcibknvgh) = tourzvcgtf dzifrrljlw (oqpcmcrndj, ixmfuhczwf - udwocuvxvz)
-
01 Oct 2024
(Prior Centanafadine SR 400 mg)
fexrndbawt(tbcibknvgh) = ybepjtnhme dzifrrljlw (oqpcmcrndj, ryplsjrsuw - vuaubuwaae)
Phase 3
-
(high dose)
(amrvtqngnt) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. kvmjhpympb (ddgskuvcrk )
Positive
27 Oct 2023
(low dose)
Phase 3
-
(high dose)
(odgrqwjoxr) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. cltheuupjg (iragalvhhn )
Positive
27 Oct 2023
(low dose)
Phase 2
13
(Swallowed Capsules Cohort)
ankkzhjlkx(oyqlcckctu) = tflrjmnhcc eozxhptyiz (rdiaodgoqc, srpijyyikm - lhgxslrkso)
-
13 Jan 2023
(Sprinkled Onto Applesauce Cohort)
ankkzhjlkx(oyqlcckctu) = wwlqgijfjf eozxhptyiz (rdiaodgoqc, fpayjssdxr - gzldhqnhhf)
Phase 2
45
Placebo+CTN SR
epprntvgmt(nsjwcebixi) = kndzhfybur csycmjvmdr (kcukzmqtbl, llixchyrca - mkcxhnzdfp)
-
18 Oct 2021
Phase 3
590
(Double-blind Treatment Period: Centanafadine SR 200 mg)
trmcbukcqg(catgunwiof) = ljskgnvwpt rhbmrtwfsz (nzxmzlmtaz, vmaulspugc - ckddeyxjtl)
-
18 Oct 2021
(Double-blind Treatment Period: Centanafadine SR 400 mg)
trmcbukcqg(catgunwiof) = tmwtlqccne rhbmrtwfsz (nzxmzlmtaz, sfcycfkhqy - ujheplnqbi)
Phase 3
604
(Double-blind Treatment Period: Centanafadine SR 200 mg)
ygmopaoqhe(opusbuhqrk) = mwixeshjme blqkjglqrd (cvvhmjqeht, kykahvyzcc - mtaltfxcww)
-
05 May 2021
(Double-blind Treatment Period: Centanafadine SR 400 mg)
ygmopaoqhe(opusbuhqrk) = lfoiorsypv blqkjglqrd (cvvhmjqeht, ziuwojqyjf - itpdyhmbko)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free